Bile Duct Cancer
Advertisement
In several different types of cancer, tumor budding is linked to poor survival outcomes.
While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.
Patients with chemotherapy-responsive disease typically undergo observation after 6 months of gemcitabine-based therapy.
Adding nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve PFS or OS in cholangiocarcinoma.
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
The study's primary end point was overall survival.
As gem/cis is linked to low survival times, various trials have attempted to improve first-line therapy outcomes for CCA.
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Treatment-related adverse events were mostly sitravatinib related and included hand-foot syndrome and hypertension.
A study investigated atezolizumab with varlilumab, an anti-CD27 human antibody, with or without cobimetinib, a MEK inhibitor.
Determining which patients can benefit the most from immunotherapy remains elusive.
TOPAZ-1's 3-year follow-up is the longest survival follow-up for a global, randomized phase III trial in this setting.
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA.
Patients who underwent targeted therapy for IDH1/2 alterations or FGFR2 fusions showed a 100% concordance rate.
The developed nomogram was found to provide significant diagnostic accuracy with an area under the curve level of 0.882.
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.